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Background: Pediatric catheterization exposes patients to varying radiation doses. Concerns over the effects of
X-ray radiation dose on the patient population have increased in recent years. This study aims at quantifying
the patient radiation dose reduction after the introduction of an X-ray imaging technology using advanced real
time image noise reduction algorithms and optimized acquisition chain for ﬂuoroscopy and exposure in a
pediatric and adult population with congenital heart disease.
Methods: Patient and radiation dose data was retrospectively collected (July 2012–February 2013) for 338
consecutive patients treated with a system using state of the art image processing and reference acquisition
chain (referred as “reference system”). The same data was collected (March–October 2013) for 329 consecutive
patients treated with the new imaging technology (Philips AlluraClarity, referred as “new system”). Patients
were divided into threeweight groups: A) below 10 kg, B) 10–40 kg, and C) over 40 kg. Radiation dosewas quan-
tiﬁed using dose area product (DAP), while procedure complexity using ﬂuoroscopy time, procedure duration
and volume of contrast medium.
Results: The new system provides signiﬁcant patient dose reduction compared to the reference system. Median
DAP values were reduced in group A) from 140.6 cGy·cm2 to 60.7 cGy·cm2, in group B) from 700.0 cGy·cm2
to 202.2 cGy·cm2 and in group C) from 4490.4 cGy·cm2 to 1979.8 cGy·cm2 with reduction of 57%, 71% and
56% respectively (p b 0.0001 for all groups).
Conclusions: Despite no other changes in procedural approach, the novel X-ray imaging technology provided
substantial radiation dose reduction of 56% or higher.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Patientswith congenital heart defects frequently undergo numerous
and repeated diagnostic and interventional catheterization procedures,
in addition to other imaging studies such as chest-X-rays and CT studies.
The growing number and complexity of interventional cardiology pro-
cedures have been signiﬁcant in the past years as a result of advances
made in transcatheter techniques and the armamentarium available
(i.e. devices, stents, percutaneous valves, miniaturized balloons, coils,
etc.) [1,2]. While their beneﬁts to the patients are undisputable, all
these procedures contribute to high accumulated radiation doses to
the patient population [3–5]. This is particularly relevant for infants
and children and even if the long term consequences of this exposureeart Defects, Heart andDiabetes
, Georgstrasse 11, D-32545 Bad
5731 972131.
land Ltd. This is an open access articlare not well understood and extremely difﬁcult to estimate, there is
now for many decades considerable concern about the possible sto-
chastic effects, such as the incidence of solid tumors and leukemia
[6–11]. In fact, growing tissue in children is more radiosensitive
than that in adults and, due to their small size, larger body parts
are irradiated during cardiac catheterization including radiosensi-
tive organs such as thyroid and eyes which are closer to the heart
[12,13]. Moreover, children with complex heart defects often need
to undergo increasingly complex procedures many times during
their lifetime, resulting in a high cumulative dose acquired [14–16].
Minimizing radiation dose is therefore crucial for this vulnerable
population, as children are likely to survive long enough through a
possible latent period and develop ormanifest late effects of early ra-
diation exposure.
Successful patient radiation dosemanagement can only be achieved
by optimization of medical imaging technology together with best
control of the equipment by the operator [17,18]. In this respect, best
practices are applied in our lab using “ALARA” radiation reductione under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
102 N.A. Haas et al. / IJC Heart & Vasculature 6 (2015) 101–109principles in terms of patient radiation safety, such as short imaging
time, avoidance of ﬁeld overlap in repeated acquisitions, low SID, tight
collimation, use of intra-procedural echocardiography, and a frame
rate for ﬂuoroscopy acquisitions of maximum 15 frames/s [19–24].
Moreover, our cath lab has been recently upgraded to a novel X-ray im-
aging technology (AlluraClarity; Philips Healthcare, Best, Netherlands)
developed for ﬂuoroscopy and cine exposure for interventional cardiol-
ogy for the entire patient size population, including pediatric. This
technology enables signiﬁcant patient entrance dose reduction
achieved by a combination of advanced real-time image noise reduction
algorithms with state-of-the-art hardware and an anatomy-speciﬁc op-
timized full acquisition chain (grid switch, beam ﬁltering, pulse width,
spot size, detector and image processing engine). Furthermore, image
quality is further positively inﬂuenced by the use of smaller focal spot
sizes and shorter pulses. Radiation dose reduction using this technology
has already been investigated in other clinical and investigational do-
mains outside congenital heart disease interventions by comparing
state-of-the-art reference to new systems [51,52]. In complex ablation
procedures, patient dose and physician dose were reduced by 40% and
50%, respectively [25]. In interventional neuroradiology, 75% patient
radiation dose reduction was demonstrated during digital subtraction
angiography (DSA)without affecting image quality [26], and 60%proce-
dural patient dose reduction was achieved [27]. However, results that
quantify the reduction of patient radiation dose enabled by this technol-
ogy for congenital heart disease are not available in literature. The study
presented here was designed to quantify the procedural patient
radiation dose reduction due to the novel X-ray imaging technology in
a patient cohort with congenital heart diseases in comparison with
our state-of-the-art angiography system.2. Methods
2.1. Patients
All 667 consecutive patients with congenital heart defects referred
between July 2012 and October 2013 were retrospectively included in
the study. Patients who received catheter investigation with echocardi-
ography only (i.e. Rashkind procedures) or under direct vision of the
area to be treated (i.e. intraoperative hybrid procedures)were excluded
from the analysis. In March 2013, the biplane ﬂat panel angiography
system was upgraded from Allura Xper FD20/10 (installed in 2011)
equipped with state-of-the-art image processing (“reference system”)
to the new AlluraClarity with Clarity IQ technology with advanced real
time image noise reduction algorithms and optimized acquisition
chain for all exposure techniques (Philips Healthcare, Best, The
Netherlands). Patients were therefore assigned to the “reference” or
“new” groups, and categorized according to clinical requirements and
technical implementation to weight: A) below 10 kg, B) 10–40 kg, and
C) over 40 kg.
The study was conducted in accordance with the provisions of the
Declaration ofHelsinki andwas approved by the local ethical committee
(approval Ref. No.: 21/2014). Procedure and dose data for all patients
admitted with congenital heart disease (CHD) in the period July
2012–February 2013 were collected. As per institutional protocol and
enforced by the European legislation, all relevant periprocedural data
were continuously monitored and documented as part of the hospital
quality assurance program. The data reported here include radiation
dose, ﬂuoroscopy time, procedure time, weight, height, BMI, and con-
trast medium use. After upgrading to the new system, procedure and
dose data information for all consecutive patients were collected during
March–October 2013. During the procedures the anti-scatter grid was
not removed. The same cardiologists were employed and the same pro-
cedural techniques were used. All our catheter interventions were per-
formed under deep conscious sedation and without general anesthesia
as described in detail elsewhere [28].2.2. Imaging technology
ClarityIQ is a novel X-ray imaging technology that combines
advanced real-time image noise reduction algorithms, with state-of-
the-art hardware to reduce patient entrance dose signiﬁcantly. This is
realized by anatomy-speciﬁc optimization of the full acquisition chain
(grid switch, beam ﬁltering, pulse width, spot size, detector and image
processing engine) for every clinical task individually. The system has
been optimized for all major disease areas using over a 1000 patients.
In addition to patient entrance dose reduction, the image quality is im-
proved through the use of the smaller focal spot sizes, and shorter
pulses and the introduction of automatic real-time motion compensa-
tion in subtraction imaging.
One of the features of ClarityIQ, temporal noise reduction, is imple-
mented by averaging consecutive images. However, in interventional
cardiology, cardiac and respiratory motion result in the appearance of
“ghost images” of moving tissues or devices. This used to limit the num-
ber of images that could be averaged, hence requiring higher doses per
frame. The implementation of a motion compensation algorithm in this
technology enables alignment of moving objects before averaging, such
that more consecutive images can be averaged to reduce noise more
signiﬁcantly.
In addition, a spatial noise reduction algorithm uses the random
nature of noise to discern between noise and useful clinical information
in a single image. When a pixel is identiﬁed as noise, its intensity is
averaged with surrounding pixels in order to ﬁlter it out. Thanks to
the powerful computational power, a larger neighborhood of pixels
can be averaged, providing more noise reduction and increasing the
conﬁdence in the clinical information to maintain in the image [26,
27]. Finally, image enhancement processing reduces low frequency
over- and under-exposed areas and enhances high frequency edges in
order to sharpen contrast. The image enhancement enabled by these
features made possible a further optimization of the X-ray acquisition
chain; this was modiﬁed to achieve patient radiation dose reduction
for both pediatric and adult population for ﬂuoroscopy and cine expo-
sure. The maximum patient entrance dose for ﬂuoroscopy was reduced
from 22 mGy/min, 44 mGy/min and 44 mGy/min in the reference sys-
tem to 7 mGy/min, 12 mGy/min and 22 mGy/min in the new system
for theﬂuoroscopymodes I, II and III respectively,with the same relative
reduction over the entire patient thickness range. For the pediatric
group, two cine applications are introduced based on patient weight:
a) below 40 kg and b) above 40 kg. The below 40 kg group uses a
small focal spot (0.4) to increase the sharpness of images. In addition,
increase in copper ﬁltration was implemented (0.4 mm Cu and
1.0 mm Al) compared to the reference pediatric cine acquisition chain
(0.0 mm Cu and 0.0 mm Al). The practical aspects of adding copper
ﬁltration to reduce patient radiation dose have been already studied
by other authors [13,52]. Photons with lower energy do not contribute
to the image quality, as they can't penetrate the patient's body, but
add needless radiation dose to the patient. Additional copper ﬁltration
enables the reduction of these photons, with consequent patient radia-
tion dose reduction.
In conclusion, hardware imaging components such as copper ﬁltra-
tion, power, pulse width and duration, and focal spot size enter a virtu-
ous cycle with advanced and real-time image processing features in
order to optimize the dose to image quality relationship for each clinical
application.
2.3. Statistical analysis
Patient radiation dose was quantiﬁed as (cumulative) dose area
product (DAP),measured by the internal transmission ionization cham-
ber (KermaX plus; IBADosimetry, Schwarzenbruck, Germany) and
displayed on the equipment as mGy·cm2; this was automatically con-
verted into cGy·cm2 for documentation purposes. In addition, acquisi-
tion parameters, such as ﬂuoroscopy time, procedure time, and
Table 1
Distribution of patients among the ≤10 kg, 10–40 kg and N40 kg group, for both the ref-
erence and the new system for all, diagnostic, and intervention procedures.
≤10 kg group 10–40 kg group N40 kg group
















100 89 119 115 109 117
Diagnostic 39 40 38 37 38 39
Intervention 61 49 81 78 71 78
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study was radiation dose quantiﬁed as DAP. Secondary outcomes were
the ﬂuoroscopy time, procedure duration, and amount of contrast
medium. These secondary outcomes were used as surrogates for case
complexity, in order to exclude this as a potential incidental difference
between the groups that could explain dose differences. The study
hypotheses were that signiﬁcant procedural dose reductions were
achieved using the new technology in all three weight groups.
Descriptive statistics were used to describe patient and procedure
characteristics, with differences between reference and new systems
evaluated with a nonparametric t-test (assuming no Gaussian distribu-
tion) at a signiﬁcance level of alpha = 0.05.
2.4. Subgroup analysis for ASD patients
Based on the absolute numbers, the timeframe of the analysis and
the large variation in procedures performed, a comprehensive subgroup
analysis per procedure typewasnot possible. However, as an illustrative
case example, we performed a sub-analysis for patients with one of the
most common procedures, interventional ASD closure. The protocol for
ASD closure is very uniform and without relevant variations other than
operator skills. This includes single plane ﬂuoroscopy for the procedure
and standard biplane cine angiography acquisitions for speciﬁc parts of
the procedure such as documentation of the balloon sizing, the wiggle
maneuver, the release process as well as a ﬁnal documentation of the
device position. All ASD closures are considered as technically simple
interventions; due to the educational character of our institution, ASD
closures are performed by registrars in training for pediatric cardiology
or junior fellows as ﬁrst operators with an experienced consultant
supporting.
2.5. Standardizing dose reporting
Efforts were undertaken in this ASD analysis to make the large vari-
ability in procedures performed aswell as in patients treated intuitively
comparable. It is of no discussion that longer procedure times will ex-
pose patients to larger radiation doses; at the same time larger patients,
i.e. those with a higher body weight and body mass index (BMI) will
require larger radiation doses for the same procedure. Whereas a num-
ber of other important parameters also inﬂuence dose levels (such as
projection angles), and whereas ﬂuoroscopy time does not include
cine exposure, these two factors were taken into account in a sub-
analysis calculating dose exposure as radiation dose perweight,ﬂuoros-
copy time, and weight × ﬂuoroscopy time [2,13,20].
3. Results
3.1. Patients
In total, the complete data set of 667 consecutive patients with con-
genital heart disease were prospectively collected and retrospectively
analyzed. There were 18 patients excluded from the dose reduction
analysis because they were treated only with echocardiography or
under direct vision as intraoperative hybrid procedure (13 patients
from the b10 kg group, 5 patients from the 10–40 kg group). Therefore,
649 patients (328 for the reference system and 321 for the new system)
were included in the analysis.
Table 1 shows the distribution of patients among the three weight
groups for both reference and new systems. The distribution between
reference and new systems among the weight groups was similar,
with a higher number of interventional than diagnostic procedures for
all weight groups.
The patient characteristics are listed in Table 2. Themeanweight for
all patients included in the analysis was 32.1 kg (SD: 27.6) and the BMI
was 17.8 kg/m2 (SD: 5.0) for diagnostic and interventional procedures.
In general there were no clinically important or statistically signiﬁcantdifferences in the group size and distribution of weight or BMI between
the Reference and New groups in any of the three weight subgroups or
the subsequent variation regarding interventional procedures or
diagnostic catheters.
3.2. Procedure characteristics
Table 3 shows the procedure characteristics for all patients in the
threeweight groups. Again, there were no statistically signiﬁcant differ-
ences in ﬂuoroscopy time between the reference and the new systems
for the three weight groups, nor in procedure time and contrast
medium for the b10 kg and N40 kg groups. However, for the 10–40 kg
group, the procedure time was signiﬁcantly lower (p = 0.028) for the
new systemwhile the parameters affecting X-ray radiation such as vol-
ume of contrast medium as well as ﬂuoroscopy time were similar be-
tween the two systems.
For diagnostic and intervention procedures separately, there were
no differences between the new and reference systems for the below
10 kg and over 40 kg groups in terms of ﬂuoroscopy time, procedure
time and contrast. However for the 10–40 kg group, the contrast medi-
um reaches signiﬁcant difference with a higher volume of contrast used
with the old system (median 80.5 ml) as compared to the new system
(median 56.5 ml) in the diagnostic group (p = 0.018).
3.3. Radiation exposure
Median DAP values decreased with the new system from 140.6
cGy·cm2 to 60.7 cGy·cm2, from 700.0 cGy·cm2 to 202.2 cGy·cm2 and
from 4490.4 cGy·cm2 to 1979.8 cGy·cm2 with reduction quantiﬁed at
57%, 71% and 56% for the below 10 kg, 10–40 kg and over 40 kg group
respectively. Patient radiation dose was signiﬁcantly reduced for the
three groups (p b 0.0001) by using the new system. Fig. 1 shows the dis-
tribution of DAP values for the reference (left) and new system (right)
for the below 10 kg, 10–40 kg and over 40 kg group respectively, for
all procedures.
For diagnostic procedures the patient dose reduction was 46%, 79%
and 46% while for the interventional procedures it was 61%, 64% and
61% for the below 10 kg, 10–40 kg and over 40 kg group respectively.
3.4. Subgroup analysis for ASD patients
A total number of 19 patients were referred to our cath lab for inter-
ventional occluder closure of a secundum atrial septal defect (ASD)
while we were using the reference system and 31 patients while we
were using the new system. Based on the relatively small absolute pa-
tient numbers, the whole cohort was analyzed without subdivision
into the different weight groups. Again there were no clinically impor-
tant or statistically signiﬁcant differences between the patients or
procedure characteristics (see Table 5). DAP decreased from 678.0
cGy·cm2 to 112.3 cGy·cm2 for the new system (reduction of 83%; p =
0.0002).
Table 2
Patient characteristics for the entire population, for the ≤10 kg, 10–40 kg and N40 kg group, for reference and new systems for all (diagnostic and intervention) procedures.
All patients ≤10 kg group 10–40 kg group N 40 kg group
Ref and New system Ref system New system p value Ref system New system p value Ref system New system p value
(n = 649) (n = 100) (n = 89) (n = 119) (n = 115) (n = 109) (n = 117)
Weight [kg]
Mean (SD) 32.1 (27.6) 6.0 (1.9) 6.3 (2.2) 0.352 20.6 (8.5) 20.6 (7.4) 0.478 68.0 (19.5) 63.6 (13.9) 0.258
Median 19.0 6.0 6.1 17.0 18.0 62.0 64.0
Min, Max 2.2, 135.0 2.3, 10.0 2.2, 10.0 10.3, 39.0 11.0, 40.0 41.0, 135.0 42.0, 116.2
Q1, Q3 8.70, 55.00 4.4, 7.5 4.7, 8.0 14.0, 27.2 15.0, 25.3 55.5, 78.0 53.0, 72.0
BMI [kg/m2]
Mean (SD) 17.8 (5.0) 14.8 (2.6) 14.3 (2.2) 0.333 15.6 (2.3) 15.4 (2.3) 0.322 23.1 (5.2) 22.4 (4.0) 0.501
Median 16.4 14.8 14.2 15.6 15.4 22.0 21.9
Min, Max 4.8, 40.1 9.8, 30.0 5.2, 19.9 4.8, 21.9 7.1, 21.5 14.7, 40.1 15.2, 34.7
Q1, Q3 14.5, 20.1 13.3, 16.1 13.3, 15.5 14.4,16.9 14.2, 16.4 19.7, 25.7 19.6, 24.6
* Ref system= Reference system, SD= Standard deviation, BMI = Body mass index.
Table 3
Procedure characteristics for the entire population, the ≤10 kg, 10–40 kg and N40 kg group, for reference and new systems for all procedures.
All patients ≤10 kg group 10–40 kg group N40 kg group
Ref and New system Ref system New system p value Ref system New system p value Ref system New system p value
(n = 649) (n = 100) (n = 89) (n = 119) (n = 115) (n = 109) (n = 117)
Procedure time [min]
Mean (SD) 83.0 (50.8) 78.0 (47.3) 68.6 (34.7) 0.227 92.3 (53.3) 81.0 (50.7) 0.029 89.3 (59.0) 85.1 (51.0) 0.787
Median 71.0 66.0 66.0 82.0 68.0 73.0 75.0
Min, Max 2.0, 392.0 22.0, 356.0 17.0, 177.0 2.0, 278.0 15.0, 270.0 4.0, 392.0 4.1, 255.0
Q1, Q3 48.0, 103.0 48.0, 96.0 44.0, 86.0 53.5, 119.5 47.0, 101.5 53.0, 110.0 47.0, 110.0
Fluoro time [min]
Mean (SD) 13.9 (15.4) 10.8 (8.1) 13.2 (26.6) 0.092 14.8 (13.1) 12.4 (10.2) 0.231 16.3 (17.4) 15.2 (12.5) 0.932
Median 9.8 9.4 7.1 10.3 9.4 10.7 11.7
Min, Max 0.1, 239.0 0.4, 56.0 0.1, 239.0 0.3, 76.5 1.2, 59.6 0.2, 119.2 0.1, 54.9
Q1, Q3 5.7, 17.3 5.6, 13.7 3.8, 13.5 6.4, 19.8 5.8, 16.3 7.1, 18.1 6.2, 22.5
CMV [ml]
n 578 99 88 107 96 92 96
Mean (SD) 85.7 (66.5) 39.1 (20.7) 45.0 (46.6) 0.717 94.5 (57.7) 81.7 (42.5) 0.145 124.2 (79.4) 128.6 (75.3) 0.652
Median 70.0 35.0 36.0 81.0 75.5 107.0 112.0
Min, Max 1.0, 495.0 6.0, 132.0 1.0, 416.0 10.0, 370.0 7.0, 210.0 5.0, 495.0 5.0, 357.0
Q1, Q3 40.0, 110.0 24.0, 50.5 25.0, 51.8 60.0, 115.0 50.0, 109.3 70.8, 161.0 79.0, 170.5
* Ref = Reference system, SD= Standard deviation, CMV = contrast medium volume.
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stantially regarding body composition (i.e. weight, length, BMI) as
well as with regard to the procedure performed (interventional vs.
diagnostic, complex vs. “simple”) and ﬁnally by the time needed to per-
form the procedure, a more detailed analysis is needed for comparison
and to estimate and judge the inﬂuence of possible radiation reduction
efforts. For this group extra efforts were undertaken to standardize the
radiation dose according to patient (i.e. weight) and procedure
characteristics (i.e. ﬂuoroscopy time). There was a signiﬁcant reduction
of radiation dose (DAP) applied as calculated by DAP/weight (reduction
72%), DAP/ﬂuoroscopy time (reduction 83%) and DAP/weight/
ﬂuoroscopy time (reduction 72%).
4. Discussion
The aim of the study was to quantify the patient dose reduction
achieved in a patient cohort with congenital heart disease enabled by
an X-ray imaging technology combining advanced real time image
noise reduction with an optimized acquisition chain for ﬂuoroscopy
and exposure in interventional cardiology for the entire population
size. The results conﬁrmed a patient dose reduction of 57%, 71% and
56% for the below 10 kg, 10–40 kg and over 40 kg group.
These results are in agreement with prior literature regarding this
technology in different patient populations and clinical domains.
Procedural patient and staff occupational dose reduction, enabled bythe technology investigated, has already been proven outside congeni-
tal heart disease interventions by comparing state-of-the-art reference
to new systems. In complex ablation procedures, patient dose and
physician dosewere reduced by 40% and 50%, respectively [25]. In inter-
ventional neuroradiology, 75% patient radiation dose reduction was
demonstrated during digital subtraction angiography (DSA) without
affecting image quality [26], and 60% procedural patient dose reduction
was achieved [27]. A preclinical study on a pigletmodel proved that DSA
radiation dose for pediatrics can be reduced by a factor four without
deterioration of image quality [51].
Patient radiation dose reduction is of extreme importance in patients
with congenital heart disease as they are subjected to repeated
procedures over the lifetime. As interventional procedures become
more and more complex and procedural complexity is correlated with
increasing ﬂuoroscopy exposure time, adequate radiation reduction is
of speciﬁc importance [29,30].
Baysson et al. reported on an epidemiological study launched in
France to provide further knowledge about the potential cancer risks
with pediatric catheterization procedures in 8000 patients [6]. Even
though the long-term risks of fatal malignancy following a single
pediatric catheter investigation seems very low, the effect of repetitive
exposure is unclear [7,31]. In general, DAP values measured during pe-
diatric catheterizations show an excellent correlation with the entrance
radiation dose and skin doses measured with thermoluminescent
dosemeters (TLDs) or can be transferred by calculation models to
Fig. 1. Distribution of DAP values for all procedures for the b10 kg (top), 10–40 kg (middle), N40 kg (bottom) group for the reference system (left) and new system (right). Dashed lines
represent the third quartile (Q3). For graph layout purposes, the x-axis might be limited with percent of displayed values greater than 97%.
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Table 4
Radiation dose for the entire population, the ≤10 kg, 10–40 kg and N40 kg group, for
reference and new systems for all procedures.
DAP [cGy·cm2]
Mean (SD) Median Min, Max Q1, Q3
All patients
Reference and new
system (n = 649)




189.0 (156.0) 140.6 10.8, 891.7 82.2, 261.9
New system
(n = 89)





1649.3 (3522.7) 700.0 33.9, 35042.3 380.8, 1688.2
New system
(n = 115)





7303.4 (10.381.6) 4490.4 45.9, 71271.2 1680.1, 8617.6
New system
(n = 117)
3840.1 (6302.6) 1979.8 0.1, 45393.2 658.1, 4977.3
p value b0.0001
Table 5
Radiation dose for ASD procedures for entire population and for reference and new sys-
tems for all weight groups.
All patients All weight groups
Ref and new system Ref system New system p value
(n = 50) (n = 19) (n = 31)
Weight [kg]
Mean (SD) 35.7 (21.7) 35.7 (22.7) 35.7 (21.4) 0.604
Median 30.0 32.0 26.0
Min, Max 10.7, 80.0 10.7, 80.0 13.0, 80.0
Q1, Q3 17.3, 49.8 14.5, 52.8 19.0, 48.0
BMI [kg/m2]
Mean (SD) 17.8 (3.7) 17.9 (3.7) 17.8 (3.7) 0.849
Median 16.4 16.3 16.4
Min, Max 12.9, 27.0 13.3, 24.7 12.9, 27.0
Q1, Q3 15.0, 20.6 15.0, 21.4 15.0, 20.0
Procedure time [min]
Mean (SD) 49.7 (22.9) 56.6 (27.3) 45.5 (18.9) 0.141
Median 43.0 47.0 42.0
Min, Max 15.0, 120.0 19.0, 104.0 15.0, 120.0
Q1, Q3 35.0, 56.8 36.5, 75.5 35.0, 53.5
Fluoro time [min]
Mean (SD) 7.3 (5.6) 8.4 (7.0) 6.6 (4.6) 0.263
Median 5.7 6.9 5.5
Min, Max 1.2, 31.8 1.2, 31.8 1.2, 24.2
Q1, Q3 3.9, 9.3 4.6, 9.0 3.8, 9.3
CMV [ml]
Mean (SD) 33.6 (26.0) 11.5 (9.2) 42.4 (25.5) 0.781
Median 22.0 11.5 50.0
Min, Max 5.0, 70.0 5.0, 18.0 10.0, 70.0
Q1, Q3 14.0, 55.0 8.3, 14.8 22.0, 60.0
DAP [cGy·cm2]
Mean (SD) 574.0 (991.6) 1048.1 (1445.2) 283.5 (350.9) 0.0002
Median 273.7 678.0 112.3
Min, Max 30.2, 6368.0 33.9, 6368.0 30.2, 1475.0
Q1, Q3 83.4, 694.5 352.0, 1014.6 68.3, 367.1
DAP/ﬂuoro time [cGy·cm2/min]
Mean (SD) 76.9 (83.2) 132.1 (103.0) 43.0 (42.8) p b 0.0001
Median 42.3 118.6 20.4
Min, Max 9.9, 413.8 10.3, 413.8 9.9, 186.8
Q1, Q3 17.2, 113.6 55.3, 176.9 14.9, 59.5
DAP/weight [cGy·cm2/kg]
Mean (SD) 24.1 (71.9) 49.6 (112.3) 8.5 (14.4) p b 0.0001
Median 7.9 15.9 4.4
Min, Max 1.3, 505.4 2.3, 505.4 1.3, 81.9
Q1, Q3 3.4, 15.9 10.7, 38.5 2.9, 7.4
DAP/weight/ﬂuoro time [cGy·cm2/kg/min]
Mean (SD) 2.6 (3.7) 4.8 (5.2) 1.2 (1.1) p b 0.0001
Median 1.5 3.2 0.9
Min, Max 0.2, 19.8 0.7, 19.8 0.2, 6.6
Q1, Q3 0.8, 2.3 1.7, 5.5 0.7, 1.5
*Ref system = Reference system, SD = Standard deviation, BMI = Body mass index,
CMV = Contrast medium volume, DAP = Dose area product.
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ment of the total amount of radiation used [4,13,32–35]. Similar results
are obtainedwhen calculating effective doses fromDAP as published by
the International Commission on Radiology Protection and measuring
the effects on DNA damage [8]. Indirect cancer risk estimations and di-
rect DNA-damage data emphasize the strict radiation dose optimization
in children [36]. UsingMonte Carlo simulations effective and equivalent
organ doses can be derived by the use of DAP in children undergoing
cardiac catheterization and estimated risk of exposure-induced death
values can be calculated [9]. Therefore the substantial reduction of
DAP values as presented here will be helpful to reduce the cumulative
radiation risk for the pediatric patientswith congenital heart defects un-
dergoing diagnostic and interventional catheter investigations as well
as for the operators performing the procedures [37].
Table 6 provides a comparison in terms of patient radiation dose
with literature. Unfortunately, variability in patient size and procedure
types, together with the different ways of reporting results in other
studies makes comparison with literature very cumbersome. For exam-
ple some authors have made an attempt of providing dose reference by
classifying the population in standardized age groups [16,34,38], while
others in weight groups [15,39–41] or ﬂuoroscopy time [42,43]. More-
over, when making comparisons in terms of patient dose, procedure
complexity should always be assessed. Procedure complexity should
be classiﬁed based on a combination of parameters such as ﬂuoroscopy
time, procedure time andnumber of exposure images or amount of con-
trastmediumused during angiography acquisitions, beside information
on frame rates used for both ﬂuoroscopy and cine acquisitions.
In accordance to other published studies reporting patient radiation
doses and procedure complexity [15,16,30], this study reports consis-
tent ﬂuoroscopy times used for diagnostic and interventional proce-
dures with the two systems across the weight groups, regardless of
procedure complexity.
Moreover, the application of best practices in our lab to minimize
ﬂuoroscopy times and cine images to clinically acceptable levels, ac-
cording guidelines [44], provide ﬂuoroscopy times which are lower
than the one reported by others [15,16], see Table 6. In light of these
best practice behaviors, it is not possible to conclusively determine
whether the lower radiation dose observed in our study on either
system compared with literature reﬂects system or operator effects.Additional standardization of the radiation dose applied to patient and
procedural factors may be helpful to differentiate these effects. We
may suggest that previous studies used state-of-the-art systems, and
could therefore be comparedwith our reference group, highlighting be-
havioral inﬂuence on dose. As the same conditions (i.e. operators, com-
plexity, etc.) were present throughout our study, we infer that the dose
reduction shown here between the reference and new systems in turn
reﬂects only system capabilities.
4.1. ASD patients sub-analysis
Wehave tried to accomplish the task of standardization by analyzing
the results of dose reduction and combining themwith the confounding
factors exposure time, weight and BMI and the combination thereof.
Table 6
Comparison of procedure characteristics and patient radiation dose with literature.





Median [Q1, Q3] Median [Q1, Q3]
Diagnostic
≤10 kg group
6.1 39 9.5 4.8, 12.6 103.9 82.2, 261.9 This Study — Reference system
6.0 40 6.6 3.5, 13.6 56.3 41.0, 129.4 This study — New system
4.5 242 26 743 433, 1433 [16]
b5 15 9, 23 224 116, 349 [15]
5–12.5 16 11, 26 418 272, 663 [15]
3.6 510 14 8, 22 228 122, 420 [2]
9.5 1429 14 9, 20 540 286, 957 [2]
10–40 kg group
17.0 38 8.8 5.2, 14.5 706.85 385.7, 1130.2 This Study — Reference system
16.4 37 7.4 4.6, 14.9 151.60 97.7, 237.3 This study — New system
11.9 134 26 1399 852, 2222 [16]
23.2 85 20 1647 904, 2494 [16]
12.5–25 13 9, 20 945 575, 1.552 [15]
25–45 14 8, 22 2722 1.563, 4.290 [15]
27.4 498 12 7, 17 1449 674, 2674 [2]
N40 kg group
61.0 38 9.6 4.0, 14.00 3144.15 1123.4, 5766.0 This Study — Reference system
63.2 39 8.8 3.6, 13.6 1697.20 225.25, 3094.00 This study — New system
50.5 130 19 3415 1584, 6029 [16]
68.7 212 25 8284 3431, 18402 [16]
45–65 14 10, 25 5595 3432, 9071 [15]
N65 16 10, 21 8959 4919, 14784 [15]
58 314 11 7, 18 4006 1569, 8168 [2]
92 76 12 7, 19 10347 2811, 15874 [2]
Intervention
≤10 kg group
5.8 61 9.3 5.9, 14.1 167.70 86.0, 276.5 This Study — Reference system
6.9 49 6.9 4.1, 13.5 65.20 47.0, 136.7 This study — New system
b5 19 12, 32 258 171, 367 [15]
5–12.5 26 14.5, 41 656 346, 1380 [15]
3.4 680 18 11, 31 276 118, 610 [2]
10–40 kg group
17.9 81 10.5 6.8, 21.2 700 384.5, 1750.8 This Study — Reference system
19.0 78 10.8 6.3, 17.1 251.60 121.3, 397.4 This study — New system
12.5–25 24 13, 44 1296 634, 3128 [15]
25–45 38 24, 59 6586 243, 9693 [15]
11.2 2231 19 11, 32 737 336, 1541 [2]
28 767 19 11, 31 1922 837, 3780 [2]
N40 kg group
63.0 71 12.6 8.3, 22.9 5681.40 1889.6, 9738.7 This Study — Reference system
64.0 78 12.80 7.1, 24.5 2223.95 791.6, 5826.2 This study — New system
45–65 24 16, 45 8514 3520, 14404 [15]
N65 36 19, 51 15841 8758, 38969 [15]
57 500 19 12, 31 5462 2370, 10418 [2]
88.4 90 20 12, 34 11600 6509, 20225 [2]
*DAP = Dose area product.
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DAP in patients during interventional electrophysiology and included
the time factor to analyze the effects of collimation on radiation expo-
sure, thus generating DAP per minute of ﬂuoroscopy in adult patients
[20]. As body size usually does not vary that substantially in adults,
this additional calculation seemed adequate. Kobayashi recently
published the results of a multicenter study by the Congenital Cardio-
vascular Interventional Study Consortium (CCISC) where the authors
tried to standardize radiation dose reporting in the pediatric cardiac
cath lab [2]. They analyzed the inﬂuence of weight as well as radiation
exposure time and recommended that Kerma area product/body
weight should be used as the standard in documenting radiation
usage in pediatric laboratories and as a baseline to compare and evalu-
ate strategies to lower radiation dosage in pediatric patients undergoing
cardiac catheterizations. Chida and coworkes could demonstrate a good
correlation between DAP and the weight of the patient as well as the
weight-ﬂuoroscopic time product indicating that bodyweight is impor-
tant for determining radiation dose to children undergoing cardiac
catheterization [10]. Similar assumptions were reported by Vergheseet al. and Glatz and coworkers who could show an inﬂuence of age,
weight and the type of intervention on the radiation dose measured
by air Kerma or DAP [15,16]. As age reﬂects body weight and the
ﬂuoroscopy time is inﬂuenced by the procedure type these inﬂuences
must be taken into account when comparing different radiation doses
of two systems.
Despite the fact that most of the procedures were performed by
registrars in training, the overall procedure time (mean 49.7 min, SD
22.9 min, median 43 min) and ﬂuoroscopy time (mean 7.3 min, SD
5.6 min, median 5.7 min) were considerably shorter than previously
reported. Fischer et al. reported a single center series using the
Amplatzer Septal Occluder (ASO) in 200patientswith amedian ﬂuoros-
copy timeof 12min [45]. TheMAGIC atrial septal defect study presented
the results of an unrestricted multi-institution routine community use
of the ASO for ASD closure in 458 patients; here the mean overall
ﬂuoroscopy time was 18.46 min (SD 12.10), for simple ASDs it was
17.66 (SD 11.07) and for complex cases 20.85 (SD 14.55) [46]. Similar
ﬂuoroscopy times exceeding a mean of 10 min are reported by many
authors [47–50].
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during transcatheter ASD closure. The mean body weight was
28.7 kg (median 21,0) and the mean ﬂuoro-time 22.3 min (median
16.5 min) [4]. They reported mean DAP doses of 1.071 cGy·cm2
(median 873 cGy·cm2). This is a considerably longer ﬂuoroscopy
time and higher DAP values as compared to our cohort with the new
system (weight: mean 35.7 kg, median 26 kg, ﬂuoro time: mean
6.6 min, median 5.5 min, DAP mean 283.5, median 112.3 cGy·cm2).
Standardization of radiation doses allows us to reveal a dose reduction
of the new system as compared to the data published by Papadopoulou
of 74% [4]. When taking the different ﬂuoroscopy times as well as the
different body weight of the patients into account the dose reduction
is equally evident; median dose/time: 20.4 vs 118.6 cGy·cm2/min =
83%; median dose/weight: 4.4 vs 15.9 cGy·cm2/kg = 72%; median
dose/weight/ﬂuoroscopy time 0.9 vs 3.2 cGy·cm2/kg/min = 72%.
4.2. Limitations of this study
The ﬁrst potential limitation was that this study was not a prospec-
tive randomized controlled trial, but a retrospective all-comer design,
whereby the two groups' data were acquired sequentially. This theoret-
ically could introduce learning curve and bias effects. However, all data
was collected in a prospective manner according to the hospitals policy
of data management and based on our quality assurance program,
making inadequate data acquisition extremely unlikely. In addition, all
cases were performed by experienced operators, making learning
curve effects also unlikely. Therefore the possibility of inadequate data
acquisition seems extremely low.
Second this study does not show the possibility to adequatelymatch
patients. Nevertheless, the data presented and the number of patients
treated in a consecutive way adequately represents the usual patient
and case load of a state of the art cath lab with a large percentage of in-
terventions. Therefore the mix of patients, diagnoses, treatmentmodal-
ities and other possible confounding factors is unlikely to have
inﬂuenced the results. In order to learn about differences in radiation
across types of procedures, further investigation is warranted using a
paired study design to ensure equivalent patient and intervention
characteristics.
Third, the clinical image qualitywas not taken into account. Based on
the personal experience of all operators involved, therewas no clinically
important difference in image quality. Based on the amount of contrast
medium applied, inadequate image quality should have led to a more
extensive use of contrast medium or additional ﬂuoroscopy time to ob-
tain additional information not available by initial standard visualiza-
tion; this was not the case. In addition patient outcomes did not
change therefore proving that image quality was sufﬁcient to perform
the clinical task as well as before.
Finally, the mode of analyzing the radiation dose in combination
with body composition (weight, BMI) as well as radiation time for stan-
dardization may be criticized. Based on the usual and large variation of
patients in the ﬁeld of congenital heart defects, it seems a very logical
approach to analyze the inﬂuence of possible radiation reduction efforts.
Only the combination of absolute radiation dose with the confounding
factors provides the capability of comparing different systems without
the need of extremely large patient numbers and clearly matched
pairs. In addition and in congruence with other authors, this approach
may contribute as a clinically relevant surrogate of radiation exposure
in this very variable patient population.
Although we showed reduced exposure in our patient population,
no data is available on the potential long term consequences with re-
spect to cancer risk. Further investigation using a longitudinal study de-
sign over the decades may be warranted. However, causal relationships
between exposure at a young age and later occurrence of adverse effects
would be difﬁcult to interpret. Perhaps speciﬁc bloodmarkersmeasured
a fewmonths after treatment may be an acceptable surrogate indicator
of future malignancy.5. Conclusion
In general, an increasing number of interventional catheter
procedures are performed in children and patients with congenital
heart defects; the justiﬁcation for these interventions are evident
because they are able to avoid, postpone, replace or facilitate complex
cardiac surgery. The complexity of these procedures may however
often result in higher radiation doses. With the introduction of the
novel X-ray imaging technology to our cath lab, we could demonstrate
a signiﬁcant and substantial reduction of the overall radiation dose
applied to the patients, quantiﬁed at 57%, 71% and 56% for the below
10 kg, 10–40 kg and over 40 kg group respectively despite no other
relevant changes in the procedural approach, the complexity of the
patients or procedures involved. When analyzing speciﬁc subgroups of
patients or procedures (i.e. ASD closure) this effect may become even
more evident. We therefore believe that these results give conﬁdence
that this technology will add substantially to the ongoing initiatives to
further limit radiation exposure and thereby reduce the risk to this
potentially vulnerable patient population.
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